Zuzana Chyra1,2,3*, Srikanth Talluri, PhD4,5*, Rao Prabhala, PhD4,5, Mehmet K. Samur, PhD6,7*, Anil Aktas-Samur, PhD8,9*, Yan Xu, MD10,11*, Aaron B. Beeler, PhD12*, Roman Hajek, MD, PhD13,14,15, Mariateresa Fulciniti, PhD10, Masood A. Shammas, PhD5,16* and Nikhil C. Munshi, MD, PhD17,18,19
1The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, Boston, MA
2Department of Hemato-Oncology,, University Hospital Ostrava, Ostrava, Czech Republic
3Department of Internal Studies, University of Ostrava, Ostrava, Czech Republic
4Dana-Farber Cancer Institute, Boston, MA
5VA Boston Healthcare System, Boston, MA
6Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
7The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
8Department of Data Science, Dana Farber Cancer Institute, Boston, MA
9Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA
10Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
11Institute of Hematology & Blood Diseases Hospital, Chinese Academic Medical Science & Peking Union Medical College, Tianjin, China
12Department of Chemistry and Center for Molecular Discovery, Boston University, Boston
13Czech Myeloma Group, Brno, Czech Republic
14Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic
15Faculty of Medicine, Department of Clinical Studies, University of Ostrava, Ostrava, Czech Republic
16The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston
17Dana-Farber Cancer Institute, Harvard Medical School, Boston
18Boston VA Healthcare System, West Roxbury, MA
19Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA